FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2136029608> ?p ?o ?g. }

• W2136029608 endingPage "1205" @default.
• W2136029608 startingPage "1195" @default.
• W2136029608 abstract "The Thai Phase III Trial of ALVAC-HIV and AIDSVAX B/E showed an estimated vaccine efficacy (VE) of 31% to prevent acquisition of human immunodeficiency virus (HIV). Here we evaluated the effect of vaccination on disease progression after infection.CD4(+) T-cell counts and HIV viral load (VL) were measured serially. The primary analysis evaluated vaccine efficacy (VEP) as the percent reduction (vaccine vs placebo) in cumulative probability of a primary composite endpoint of clinical and CD4(+) count components at prespecified time points after infection. Secondary analyses of biomarker-based endpoints were assessed using marginal mean and linear mixed models.There were 61 endpoints in the modified intent-to-treat cohort (mITT; n = 114). There was no evidence for efficacy at 30, 42, 54, and 60 months in the mITT and per protocol (n = 90) cohorts. Estimated VEP (mITT) was15.8% (-21.9, 41.8) at 60 months postinfection. There was weak evidence of lower VL and higher CD4(+) count at 60 and 66 months in the vaccine group. Lower mucosal VL was observed among vaccine recipients, primarily in semen (P = .04).Vaccination did not affect the clinical course of HIV disease after infection. A potential vaccine effect on the genital mucosa warrants further study." @default.
• W2136029608 created "2016-06-24" @default.
• W2136029608 creator A5001108158 @default.
• W2136029608 creator A5001119457 @default.
• W2136029608 creator A5002299399 @default.
• W2136029608 creator A5003506474 @default.
• W2136029608 creator A5005978177 @default.
• W2136029608 creator A5006743328 @default.
• W2136029608 creator A5010028473 @default.
• W2136029608 creator A5015206660 @default.
• W2136029608 creator A5019094179 @default.
• W2136029608 creator A5025949472 @default.
• W2136029608 creator A5027015893 @default.
• W2136029608 creator A5035939404 @default.
• W2136029608 creator A5036265394 @default.
• W2136029608 creator A5045848738 @default.
• W2136029608 creator A5049346220 @default.
• W2136029608 creator A5059593998 @default.
• W2136029608 creator A5061812538 @default.
• W2136029608 creator A5067116248 @default.
• W2136029608 creator A5068721425 @default.
• W2136029608 creator A5072696926 @default.
• W2136029608 creator A5076243921 @default.
• W2136029608 creator A5076820552 @default.
• W2136029608 creator A5081163351 @default.
• W2136029608 creator A5083172737 @default.
• W2136029608 creator A5083488297 @default.
• W2136029608 creator A5085731242 @default.
• W2136029608 creator A5089514918 @default.
• W2136029608 date "2012-07-26" @default.
• W2136029608 modified "2023-10-13" @default.
• W2136029608 title "Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E" @default.
• W2136029608 cites W145219583 @default.
• W2136029608 cites W1965175217 @default.
• W2136029608 cites W1969498684 @default.
• W2136029608 cites W1970640392 @default.
• W2136029608 cites W1971556046 @default.
• W2136029608 cites W1976608858 @default.
• W2136029608 cites W1984329853 @default.
• W2136029608 cites W1997677784 @default.
• W2136029608 cites W2000564337 @default.
• W2136029608 cites W2012139740 @default.
• W2136029608 cites W2016844693 @default.
• W2136029608 cites W2017786248 @default.
• W2136029608 cites W2019780144 @default.
• W2136029608 cites W2032267362 @default.
• W2136029608 cites W2034160159 @default.
• W2136029608 cites W2039473791 @default.
• W2136029608 cites W2054390178 @default.
• W2136029608 cites W2061508375 @default.
• W2136029608 cites W2071061747 @default.
• W2136029608 cites W2073140442 @default.
• W2136029608 cites W2075345074 @default.
• W2136029608 cites W2079280846 @default.
• W2136029608 cites W2084808899 @default.
• W2136029608 cites W2088014625 @default.
• W2136029608 cites W2094829985 @default.
• W2136029608 cites W2098590425 @default.
• W2136029608 cites W2099067260 @default.
• W2136029608 cites W2100720499 @default.
• W2136029608 cites W2103920597 @default.
• W2136029608 cites W2104823480 @default.
• W2136029608 cites W2107480564 @default.
• W2136029608 cites W2108868448 @default.
• W2136029608 cites W2126851513 @default.
• W2136029608 cites W2131674674 @default.
• W2136029608 cites W2133919033 @default.
• W2136029608 cites W2146634980 @default.
• W2136029608 cites W2148391396 @default.
• W2136029608 cites W2150249219 @default.
• W2136029608 cites W2152048324 @default.
• W2136029608 cites W2156557297 @default.
• W2136029608 cites W2162457545 @default.
• W2136029608 cites W2171536421 @default.
• W2136029608 cites W2330519285 @default.
• W2136029608 cites W4237837302 @default.
• W2136029608 doi "https://doi.org/10.1093/infdis/jis478" @default.
• W2136029608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22837492" @default.
• W2136029608 hasPublicationYear "2012" @default.
• W2136029608 type Work @default.
• W2136029608 sameAs 2136029608 @default.
• W2136029608 citedByCount "52" @default.
• W2136029608 countsByYear W21360296082012 @default.
• W2136029608 countsByYear W21360296082013 @default.
• W2136029608 countsByYear W21360296082014 @default.
• W2136029608 countsByYear W21360296082015 @default.
• W2136029608 countsByYear W21360296082016 @default.
• W2136029608 countsByYear W21360296082017 @default.
• W2136029608 countsByYear W21360296082018 @default.
• W2136029608 countsByYear W21360296082019 @default.
• W2136029608 countsByYear W21360296082020 @default.
• W2136029608 countsByYear W21360296082021 @default.
• W2136029608 countsByYear W21360296082022 @default.
• W2136029608 countsByYear W21360296082023 @default.
• W2136029608 crossrefType "journal-article" @default.
• W2136029608 hasAuthorship W2136029608A5001108158 @default.
• W2136029608 hasAuthorship W2136029608A5001119457 @default.
• W2136029608 hasAuthorship W2136029608A5002299399 @default.

• next